Important Safety Information

Indication:
Aklief® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Adverse Events:
The most common adverse reactions (incidence ≥ 1%) in patients treated with Aklief Cream were application site irritation, application site pruritus (itching), and sunburn.

Warnings/Precautions:
Patients using Aklief Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of Aklief Cream, suspend or discontinue use. Avoid application of Aklief Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with Aklief Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional Important Safety Information and full Prescribing Information, visit www.AKLIEF.com.

*Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.

©2020 Galderma Laboratories, L.P. All Rights Reserved. All trademarks are the property of their respective owners.

AkLIEF®
(trifarotene)
Cream, 0.005%

INNOVATION IN ACNE TREATMENT

• Contains first retinoid molecule FDA approved for the treatment of acne in over 20 years.
• Only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.¹
• First topical treatment specifically studied to treat both facial (forehead cheeks, nose and chin) and truncal (chest, shoulders and back) acne.²

PROVEN RESULTS

• Represents the first large-scale randomized Phase 3 trials (n=2,420 patients) to simultaneously evaluate a topical therapy for the treatment of both facial and truncal acne.
• Significantly reduced inflammatory lesions as early as two weeks on the face and four weeks on the chest, shoulders and back compared to vehicle (p<0.05).³
• In Phase 3 trials, the most common reported treatment-emergent adverse events (TEAEs) were application site pain, application site dryness, application site discoloration, and application site rash.³

ABOUT ACNE

• The most common skin disease in the United States, affecting up to 50 million Americans annually.
• While acne occurs most commonly on the face, more than half of the people with facial acne (52%) also have truncal acne.⁴
• Tends to affect women more often than men and adult-onset acne is becoming increasingly common in women after their 20s and beyond. Back acne, once thought to be a predominantly male disease, has been shown to be prevalent in females.⁴
• Acne can leave physical, as well as psychological and emotional, scars. It can trigger feelings of depression, poor body image and low self-esteem, and truncal acne can add to the emotional burden of the condition.²,⁶

¹Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.

Important Safety Information

Indication: Aklief® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with Aklief Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using Aklief Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of Aklief Cream, suspend or discontinue use. Avoid application of Aklief Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with Aklief Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional Important Safety Information and full Prescribing Information, visit www.AKLIEF.com.